Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Pearce IP BioBlast®: w/e 28 May 2021

by | May 31, 2021

24 May 21 | IN | Zydus Cadila announced it has launched Ujvira (trastuzumab emtansine) in India. Ujvira is an antibody drug conjugate biosimilar and is available in 100mg and 160mg vials at a considerable discount to the reference product.

25 May 21 | BioFactura announced the initiation of Ph I trials of BFI-751 (proposed ustekinumab biosimilar). The trial is being conducted across three sites in Australia and New Zealand.

25 May 21 | AbbVie announced it will present new data from a number of studies on its immunology products including Rinvoq® (upadacitinib), Skyrizi® (risankizumab) and Humira® (adalimumab) at the EULAR 2021 Virtual Congress of Rheumatology.

28 May 21 |  Sun Pharma announced in its Q1 2021 earnings call that it will develop biosimilar products which have ‘significant future expiry dates’, aiming to be among the first approvals of ‘third wave’ biosimilar products.

Did you know that you can subscribe to Pearce IP’s updates including our weekly BioBlast® and regular pharma and IP industry news? Click here to receive these updates directly in your inbox.





Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News